Takeda Updates on China NMPA Approval of LIVTENCITY (maribavir) for the Treatment of Adults with Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies.
In: Professional Services Close-Up, 2024-01-09, S. 2024
serialPeriodical
Zugriff:
Titel: |
Takeda Updates on China NMPA Approval of LIVTENCITY (maribavir) for the Treatment of Adults with Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies.
|
---|---|
Zeitschrift: | Professional Services Close-Up, 2024-01-09, S. 2024 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
Sonstiges: |
|